Order Article Reprints

Jamroz-Wiśniewska A, Zajdel R, Słowik A, Marona M, Wnuk M, Adamczyk-Sowa M, Adamczyk B, Lasek-Bal A, Puz P, Stęposz A, et al. Modified Rio Score with Platform Therapy Predicts Treatment Success with Fingolimod and Natalizumab in Relapsing-Remitting Multiple Sclerosis Patients. Journal of Clinical Medicine. 2021; 10(9):1830. https://doi.org/10.3390/jcm10091830

Jamroz-Wiśniewska, Anna, Radosław Zajdel, Agnieszka Słowik, Monika Marona, Marcin Wnuk, Monika Adamczyk-Sowa, Bożena Adamczyk, Anetta Lasek-Bal, Przemysław Puz, Arkadiusz Stęposz, and et al. 2021. "Modified Rio Score with Platform Therapy Predicts Treatment Success with Fingolimod and Natalizumab in Relapsing-Remitting Multiple Sclerosis Patients" Journal of Clinical Medicine 10, no. 9: 1830. https://doi.org/10.3390/jcm10091830

Jamroz-Wiśniewska, A., Zajdel, R., Słowik, A., Marona, M., Wnuk, M., Adamczyk-Sowa, M., Adamczyk, B., Lasek-Bal, A., Puz, P., Stęposz, A., Krzystanek, E., Patalong-Ogiewa, M., Pokryszko-Dragan, A., Budrewicz, S., Koziarska, D., Karbicka, A., Wawrzyniak, S., Fryze, W., Furtak-Niczyporuk, M., & Rejdak, K. (2021). Modified Rio Score with Platform Therapy Predicts Treatment Success with Fingolimod and Natalizumab in Relapsing-Remitting Multiple Sclerosis Patients. Journal of Clinical Medicine, 10(9), 1830. https://doi.org/10.3390/jcm10091830